{
  "docId": "019de075-4481-714f-9573-a4ad96e0f148",
  "docSlug": "816ee2fbc8fb2bf52edc4f2891aaa98f",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 27 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 8,
  "pageCount": 27,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a comparison framework to contrast existing treatments for other conditions with the lack of treatments for FSAD.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4481-714f-9573-a4ad96e0f148/8",
  "deckHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148",
  "deckJsonHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148.json",
  "deckAnchorHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.174,
        "w": 0.138,
        "x": 0.697,
        "y": 0.51
      },
      "kind": "callout",
      "text": "No Approved Products",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d80f6381-3003-440a-be62-9f1006c48f5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.27,
        "w": 0.67,
        "x": 0.165,
        "y": 0.414
      },
      "kind": "diagram",
      "text": "Comparison of sexual dysfunction categories and their respective product availability.",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1713557c-846b-49c1-be76-45db1c897ab3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.762,
        "x": 0.119,
        "y": 0.289
      },
      "kind": "paragraph",
      "text": "Via the 2016 draft guidance document* for HSDD and FSAD, the FDA acknowledged FSAD as a distinct disorder from other forms of Female Sexual Dysfunction.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db83270e-04c8-4864-85c6-8842d29a6e2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.378,
        "x": 0.503,
        "y": 0.763
      },
      "kind": "source-note",
      "text": "* FDA 2016 draft guidance document https://www.fda.gov/regulatory-information/search-fda-guidance-documents/low-sexual-interest-desire-andor-arousal-women-developing-drugs-treatment-guidance-industry",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e805448-c514-4b51-ab1c-fa50f4f91bb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.442,
        "x": 0.279,
        "y": 0.198
      },
      "kind": "title",
      "text": "FSAD – Distinct Sexual Dysfunction",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a5b8cb0-c2fd-453c-99ac-23acf4f7ef57",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "edbd0c76-2ff3-4c05-8fca-178546a67cf7",
      "evidence": "FSAD as a distinct disorder from other forms of Female Sexual Dysfunction.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "25267a87-78d4-40f5-aa36-b6322db69654",
      "evidence": "Contrasts categories of sexual dysfunction with existing products against FSAD which has none.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 13,
      "from": 8,
      "beatId": "62556c1f-0dae-4aea-8929-81d2d36a8468",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slides 8-13 present FSAD as a distinct sexual dysfunction, its clinical issue, and the patient's experience",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "946bdaf4-2f0d-4bd9-b675-a10399e70a25",
      "evidence": "The deck implies that not treating FSAD has significant consequences, but does not explicitly state the cost of inaction",
      "position": 0,
      "objective": "What is the cost of not treating FSAD?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}